RIGL (Rigel Pharmaceuticals) Cyclically Adjusted Revenue per Share: $8.43 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RIGL Rigel Pharmaceuticals Inc RIGL
75 GF Score
Price $41.70
GF Value $26.78
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Rigel Pharmaceuticals Cyclically Adjusted Revenue per Share?

Rigel Pharmaceuticals RIGL +3.71% 75 Cyclically Adjusted Revenue per Share is $8.43 as of Jun. 2026. GuruFocus rates RIGL with a GF Score™ of 75/100 and a GF Value™ of $26.78 (Significantly Overvalued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Rigel Pharmaceuticals's adjusted revenue per share for the three months ended in Jun. 2026 was $4.022. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $8.43 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Rigel Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was -100.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 14.50% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 17.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Rigel Pharmaceuticals was 21.40% per year. The lowest was -13.90% per year. And the median was -6.00% per year.

As of today (2026-08-10), Rigel Pharmaceuticals's current stock price is $41.70. Rigel Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was $8.43. Rigel Pharmaceuticals's Cyclically Adjusted PS Ratio of today is 4.95.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Rigel Pharmaceuticals was 14.79. The lowest was 1.32. And the median was 3.50.


Rigel Pharmaceuticals  (NAS:RIGL) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Rigel Pharmaceuticals's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=41.70/8.43
=4.95

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Rigel Pharmaceuticals was 14.79. The lowest was 1.32. And the median was 3.50.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Rigel Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms


Rigel Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Rigel Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rigel Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

Rigel Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.25 5.10 5.64 6.27 7.65

Rigel Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.22 7.44 7.65 8.04 8.43

RIGL vs SGP, OCS, GYRE: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Rigel Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rigel Pharmaceuticals Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rigel Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Rigel Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


RIGL
75GF Score
Rigel Pharmaceuticals Inc RIGL
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rigel Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Rigel Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=4.022/333.9520*333.9520
=4.022

Current CPI (Jun. 2026) = 333.9520.

Rigel Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.394 241.428 0.545
201612 0.303 241.432 0.419
201703 0.315 243.801 0.431
201706 0.000 244.955 0.000
201709 0.072 246.819 0.097
201712 0.000 246.524 0.000
201803 0.000 249.554 0.000
201806 0.111 251.989 0.147
201809 0.292 252.439 0.386
201812 2.270 251.233 3.017
201903 0.755 254.202 0.992
201906 0.622 256.143 0.811
201909 1.244 256.759 1.618
201912 0.919 256.974 1.194
202003 3.308 258.115 4.280
202006 0.950 257.797 1.231
202009 1.089 260.280 1.397
202012 1.091 260.474 1.399
202103 4.601 264.877 5.801
202106 1.543 271.696 1.897
202109 1.261 274.310 1.535
202112 1.193 278.802 1.429
202203 0.974 287.504 1.131
202206 1.732 296.311 1.952
202209 1.297 296.808 1.459
202212 3.104 296.797 3.493
202303 1.502 301.836 1.662
202306 1.549 305.109 1.695
202309 1.614 307.789 1.751
202312 2.053 306.746 2.235
202403 1.686 312.332 1.803
202406 2.099 314.175 2.231
202409 3.134 315.301 3.319
202412 3.209 315.605 3.396
202503 2.935 319.799 3.065
202506 5.599 322.561 5.797
202509 3.626 324.800 3.728
202512 3.452 324.054 3.557
202603 2.988 330.213 3.022
202606 4.022 333.952 4.022

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $8.43 mean?
Rigel Pharmaceuticals (RIGL) has a Cyclically Adjusted Revenue per Share of $8.43 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Rigel Pharmaceuticals and its competitors.
Is Rigel Pharmaceuticals' Cyclically Adjusted Revenue per Share too high?
Rigel Pharmaceuticals' current Cyclically Adjusted Revenue per Share is $8.43. Overall, Rigel Pharmaceuticals has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Rigel Pharmaceuticals' Cyclically Adjusted Revenue per Share compare to SGP and OCS?
Rigel Pharmaceuticals' Cyclically Adjusted Revenue per Share of $8.43 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Rigel Pharmaceuticals and its competitors. Rigel Pharmaceuticals's current Cyclically Adjusted Revenue per Share is $8.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rigel Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Rigel Pharmaceuticals (RIGL) is currently considered Significantly Overvalued. The stock's GF Value™ is $26.78, compared to a current price of $41.70 — trading 55.7% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is $8.43. Rigel Pharmaceuticals' overall GF Score™ is 75/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Rigel Pharmaceuticals (RIGL), the current Cyclically Adjusted Revenue per Share is $8.43 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rigel Pharmaceuticals (RIGL) Overvalued in 2026?

Based on GuruFocus' analysis, Rigel Pharmaceuticals stock appears to be overvalued. The current stock price of $41.70 is trading 55.7% above its estimated GF Value™ of $26.78. GuruFocus considers Rigel Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for RIGL:

  • Cyclically Adjusted Revenue per Share: $8.43
  • GF Value™: $26.78 vs. price of $41.70 (55.7% above fair value)
  • GF Score™: 75/100 with 8 warning signs

No single metric tells the full story. See the RIGL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Rigel Pharmaceuticals Business Description

Other Exchanges RI2:Germany
Address 611 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
75GF Score

Get the complete analysis for RIGL

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$41.70
Price
$26.78
GF Value